Comparative Pharmacology
Head-to-head clinical analysis: CHOLBAM versus CRENESSITY.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHOLBAM versus CRENESSITY.
CHOLBAM vs CRENESSITY
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cholic acid is a primary bile acid that acts as a peroxisome proliferator-activated receptor alpha (PPARα) agonist, reducing the synthesis of bile acids from cholesterol via feedback inhibition of the rate-limiting enzyme cholesterol 7α-hydroxylase (CYP7A1). It also improves bile flow and reduces the accumulation of toxic bile acid intermediates.
CRENESSITY is a selective antagonist of the C-C chemokine receptor type 5 (CCR5), blocking HIV-1 entry into cells by binding to CCR5 and preventing gp120 interaction.
10-15 mg/kg orally once daily; maximum daily dose 500 mg.
300 mg orally once daily with food.
None Documented
None Documented
Terminal elimination half-life approximately 3.5-7 hours in patients with primary bile acid synthesis disorders; may be prolonged in severe hepatic impairment.
Terminal elimination half-life approximately 20 hours, supporting once-daily dosing.
Primarily biliary (fecal) excretion as conjugates; less than 5% renal excretion as unchanged drug and metabolites.
Primarily hepatobiliary excretion into feces; less than 5% excreted renally as unchanged drug.
Category C
Category C
Bile Acid
Bile Acid